Welcome

Welcome!

I hope everyone had a great and relaxing summer and is ready to continue our incredible EPAD journey. The EPAD Longitudinal Cohort Study (LCS) is well under way and EPAD is extending its Trial Delivery Center Network beyond the wave 1 TDCs thereby greatly increasing its capacity to recruit research participants into the LCS. Also congratulations to our IMI sister project AMYPAD that officially kicked-off on October 1st. Work is already underway to set up the collaboration and incorporate amyloid PET imaging into the LCS.

In the meantime WP4 and the legal team are hard at work setting up the EPAD proof-of-concept framework, which you will hear all about in a special issue of the EPAD newsletter that will arrive in your mailbox in January 2017.

This electronic newsletter will be published quarterly and be accessible via the EPAD website (www.epad.org) and inform the Alzheimer community on EPAD’s main achievements, upcoming events as well as allow you to meet the scientists who make it all happen.

In this issue, we focus on EPAD’s recommendations for the detection of early preclinical Alzheimer’s Disease that were recently published by EPAD’s Clinical Endpoints Scientific Advisory Group. We also bring you highlights from the July 2016 AAIC EPAD symposium in Toronto and you can find out more about 2 of the EPAD collaborators, Karen Ritchie and Sean Knox.

We hope you enjoy this issue of the EPAD newsletter! Happy Reading!  

Serge Van der Geyten

EPAD Coordinator

The Story behind the Picture

EPAD features prominently at AAIC Conference in Toronto

The Alzheimer’s Association International Conference took place in Toronto from 23 to 28 July. EPAD - funded by the Innovative Medicines Initiative (IMI) - featured in a number of key symposia and communications: At a joint pre-conference meeting of the Global Alzheimer’s Platform and EPAD on global Alzheimer’s research collaboration on 22 July, EPAD researchers Simon Lovestone (University of Oxford), …

Read more.

Interview with Karen Ritchie

What is your current role in EPAD? I am co-chair with Michael Ropacki of the Clinical and Cognitive Outcomes Scientific Advisory Group (CCO-SAG), which is part of WP1. I am also a member of the Epidemiology Advisory Group. The CCO-SAG includes leading neuropsychologists and neurologists from Europe and the USA, and our work has principally centered on the challenging task …

Read more.

EPAD present(s) @

• EPAD symposium "Changing how we communicate about Alzheimer’s Disease" at the 26th Alzheimer Europe Conference - Copenhagen (Denmark) - October 30 - November 2

• EPAD present at "Conférence Publique Prévenir la Maladie d'Alzheimer en Suisse: un But Atteignable" - Geneva (Switzerland) - November 10

• EPAD presentation at the Slovak Presidency of the Council of the European Union 2016 Symposium - Bratislava (Slovakia) - November 29